Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome

UMMS Affiliation

Information Services, Academic Computing Services; Department of Cell Biology; Department of Pathology

Publication Date


Document Type



Cancer Biology | Oncology | Pathology


Hypocellular myelodysplastic syndrome (MDS) represents only a small portion of MDS, of which, the clinical significance has not been well-defined. By using currently accepted age-adjusted criteria to define hypocellularity as 70 years old, we identified 163 (15.5%) hypocelluar MDS from 1049 consecutive adult MDS patients over an 11-year period (1995-2006). Compared to normal/hypercellular MDS, hypocellular MDS patients were younger (p<0.01), less anemic (p=0.02), but more neutropenic (p<0.001) and thrombocytopenic (p=0.05), and had a comparable cytogenetic risk group distribution (p=0.09) and international prognostic scores (IPSS, p=0.13). With a median follow-up of 52 months, hypocellular MDS showed a favorable overall survival (56 months versus 28 months, log-rank p<0.0001) over normal/hypocellular MDS, and this survival preference was also demonstrated in all IPSS groups and cytogenetic risk groups, and was independent of all other risk factors (Cox regression test, p=0.01). In conclusion, our study demonstrated that hypocellular MDS has characteristic clinicopathologic features, and bone marrow hypocellularity in MDS is an independent factor which predicts a favorable outcome.

DOI of Published Version



Leuk Res. 2008 Apr;32(4):553-8. Epub 2007 Sep 20. Link to article on publisher's site

Journal/Book/Conference Title

Leukemia research

Related Resources

Link to article in PubMed

PubMed ID